lefamulin - search results

xenleta solution

sunovion pharmaceuticals canada inc - lefamulin (lefamulin acetate) - solution - 10mg - lefamulin (lefamulin acetate) 10mg - other miscellaneous antibacterial agents*

Canada - English - Health Canada

xenleta tablet

sunovion pharmaceuticals canada inc - lefamulin (lefamulin acetate) - tablet - 600mg - lefamulin (lefamulin acetate) 600mg - other miscellaneous antibacterial agents*

United States - English - NLM (National Library of Medicine)

xenleta- lefamulin acetate injection, solution citric buffered normal saline- anhydrous citric acid injection, solution xenlet

nabriva therapeutics us, inc. - lefamulin acetate (unii: hdn0b924x4) (lefamulin - unii:21904a5386) - xenleta is indicated for the treatment of adults with community-acquired bacterial pneumonia (cabp) caused by the following susceptible microorganisms: streptococcus pneumoniae , staphylococcus aureus (methicillin-susceptible isolates), haemophilus influenzae , legionella pneumophila , mycoplasma pneumoniae , and chlamydophila pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of xenleta and other antibacterial drugs, xenleta should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xenleta is contraindicated in patients with known hypersensitivity to lefamulin, pleuromutilin class drugs, or any of the components of xenleta. xenleta table

European Union - English - EMA (European Medicines Agency)

xenleta

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibacterials for systemic use, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed.consideration should be given to official guidance on the appropriate use of antibacterial agents.